# Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

> **NCT00202995** · PHASE4 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 91 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer Acetate
- **DRUG:** Betaseron
- **DRUG:** Rebif

## Key facts

- **NCT ID:** NCT00202995
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** Slow enrollment decreased sample size No unexpected safety issues.
- **Last updated:** 2010-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00202995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00202995, "Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00202995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*